D J Horne1, C Spitters, M Narita. 1. Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA. dhorne@u.washington.edu
Abstract
SETTING: The use of a rifamycin in anti-tuberculosis treatment regimens is crucial for shortening treatment and achieving favorable outcomes. Rifampin (RMP) is the recommended rifamycin, although adverse effects (AEs) may require its discontinuation. The use of rifabutin (RFB), a rifamycin with activity against Mycobacterium tuberculosis, in patients with an RMP-related AE has not been well studied. OBJECTIVE: To review our experience with RFB in tuberculosis (TB) treatment. METHODS: We included TB patients who received RFB in their treatment regimens from 2003 to 2009. We evaluated the indications for RFB and, if applicable, the likelihood that RMP caused an AE. We identified RMPrelated AEs associated with RFB intolerance. RESULTS: One hundred subjects were included. The indications for RFB use were RMP-related AE (57%), con- current antiretroviral therapy (21%), potential/actual interaction with other medications (14%), and as part of an alternative regimen in liver disease (8%). Nineteen patients experienced an AE while taking RFB. Among patients with a prior RMP-related AE, 80% of whom were successfully treated with RFB, only a dermatologic AE was associated with subsequent RFB intolerance. CONCLUSIONS: Our study suggests that RFB is well tolerated by patients who develop RMP-related AEs. There may be an increased risk for RFB-related AE in patients who experienced RMP-related dermatologic events.
SETTING: The use of a rifamycin in anti-tuberculosis treatment regimens is crucial for shortening treatment and achieving favorable outcomes. Rifampin (RMP) is the recommended rifamycin, although adverse effects (AEs) may require its discontinuation. The use of rifabutin (RFB), a rifamycin with activity against Mycobacterium tuberculosis, in patients with an RMP-related AE has not been well studied. OBJECTIVE: To review our experience with RFB in tuberculosis (TB) treatment. METHODS: We included TBpatients who received RFB in their treatment regimens from 2003 to 2009. We evaluated the indications for RFB and, if applicable, the likelihood that RMP caused an AE. We identified RMPrelated AEs associated with RFB intolerance. RESULTS: One hundred subjects were included. The indications for RFB use were RMP-related AE (57%), con- current antiretroviral therapy (21%), potential/actual interaction with other medications (14%), and as part of an alternative regimen in liver disease (8%). Nineteen patients experienced an AE while taking RFB. Among patients with a prior RMP-related AE, 80% of whom were successfully treated with RFB, only a dermatologic AE was associated with subsequent RFB intolerance. CONCLUSIONS: Our study suggests that RFB is well tolerated by patients who develop RMP-related AEs. There may be an increased risk for RFB-related AE in patients who experienced RMP-related dermatologic events.
Authors: S Schwander; S Rüsch-Gerdes; A Mateega; T Lutalo; S Tugume; C Kityo; R Rubaramira; P Mugyenyi; A Okwera; R Mugerwa Journal: Tuber Lung Dis Date: 1995-06
Authors: Rajith K R Rajoli; Paul Curley; Justin Chiong; David Back; Charles Flexner; Andrew Owen; Marco Siccardi Journal: J Infect Dis Date: 2019-05-05 Impact factor: 5.226
Authors: Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid Journal: Open Forum Infect Dis Date: 2022-06-15 Impact factor: 4.423
Authors: Ivy Rukasha; Halima M Said; Shaheed V Omar; Hendrik Koornhof; Andries W Dreyer; Alfred Musekiwa; Harry Moultrie; Anwar A Hoosen; Gilla Kaplan; Dorothy Fallows; Nazir Ismail Journal: Front Microbiol Date: 2016-12-05 Impact factor: 5.640